BMI's Impact on Lung Cancer Treatment Varies by Therapy Type

New study reveals differing mortality risks for immunotherapy and chemotherapy based on patients' body mass index.

Research by Osaka Metropolitan University examined over 500,000 advanced non-small cell lung cancer patients.
Higher BMI generally lowers mortality risk in both immunotherapy and chemotherapy, up to a BMI of 24.
For patients with a BMI under 28, immunotherapy shows a lower mortality risk compared to chemotherapy.
Patients with a BMI of 28 or higher face increased mortality risk with immunotherapy, while chemotherapy remains safer.
Factors such as age, hormones, and gut microbiota also influence immunotherapy effectiveness, highlighting the need for precision medicine.